



## Summary of Studies Supporting USDA Product Licensure

Establishment Name	Zoetis Inc.
USDA Vet Biologics Establishment Number	190
Product Code	2665.06
True Name	Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Spirovac L5 - No distributor specified Spirovac L5 - Zoetis Argentina Spirovac L5 - Zoetis Colombia S.A.S. Spirovac L5 - Zoetis Mexico
Date of Compilation Summary	June 21, 2022

**Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.**

<b>Study Type</b>	Efficacy
<b>Pertaining to</b>	<i>Leptospira interrogans</i> serovar <i>canicola</i> ( <i>L. canicola</i> )
<b>Study Purpose</b>	Demonstration of efficacy against leptospirosis caused by <i>L. canicola</i>
<b>Product Administration</b>	One dose administered intramuscularly
<b>Study Animals</b>	15 Calves approximately 6 months of age; 10 vaccinates and 5 controls. All animals were seronegative for <i>Leptospira canicola</i> , <i>icterohaemorrhagiae</i> , <i>hardjo</i> , <i>grippityphosa</i> , <i>pomona</i> .
<b>Challenge Description</b>	Animals were challenged 3 weeks following vaccination.
<b>Interval observed after challenge</b>	Animals were observed post challenge for 8 days. Body temperatures and blood samples were collected daily.
<b>Results</b>	<p><u>Leptospira Isolation Results in Blood:</u>  Controls: 5/5 (100%) positive  Vaccinates: 0/10 (0%) positive</p> <p><u>Temperature Results:</u>  Controls: 5/5 (100%) positive  Vaccinates: 0/10 (0%) positive</p> <p>See the following tables for individual raw data</p>
<b>USDA Approval Date</b>	09/13/1977

Blood culture for isolation of Leptospire:

Treatment Group	Animal ID	Study Day (Challenge was on Day 0)							
		1	2	3	4	5	6	7	8
CONTROLS	45	+	+	+	-	-	-	-	-
	68	+	+	-	-	-	-	-	-
	75	+	+	+	-	-	-	-	-
	86	+	+	-	-	-	-	-	-
	106	+	+	+	-	-	-	-	-
VACCINATES	39	-	-	-	-	-	-	-	-
	57	-	-	-	-	-	-	-	-
	63	-	-	-	-	-	-	-	-
	67	-	-	-	-	-	-	-	-
	82	-	-	-	-	-	-	-	-
	85	-	-	-	-	-	-	-	-
	92	-	-	-	-	-	-	-	-
	99	-	-	-	-	-	-	-	-
	103	-	-	-	-	-	-	-	-
	104	-	-	-	-	-	-	-	-

+: Leptospire detected; -: Leptospire not detected

Temperature in °F:

Treatment Group	Animal ID	Study Day (Challenge was on Day 0)								
		0	1	2	3	4	5	6	7	8
CONTROLS	45	102.4	101.0	104.4	107.2	106.2	103.6	103.8	101.6	100.8
	68	102.2	102.0	106.6	106.8	103.6	101.2	102.8	101.0	100.6
	75	102.0	102.0	102.0	106.6	106.4	101.4	101.6	101.6	101.8
	86	102.4	103.4	105.6	106.4	105.2	101.8	102.4	102.0	102.0
	106	102.0	102.0	104.0	104.8	104.4	102.8	101.6	101.4	101.0
VACCINATES	39	102.2	101.6	102.0	102.0	102.0	102.0	102.6	103.0	102.2
	57	101.2	102.0	101.4	101.0	101.0	100.2	100.8	100.8	100.2
	63	101.6	101.0	101.0	100.8	100.6	100.4	101.0	101.0	101.4
	67	102.0	102.0	101.6	101.0	101.4	101.8	101.8	101.6	102.0
	82	102.4	102.4	101.6	100.8	101.4	101.0	101.8	102.2	100.2
	85	100.8	102.8	101.4	100.4	100.6	100.2	100.6	101.0	100.8
	92	102.0	101.6	101.0	100.6	100.8	100.0	101.4	101.6	101.2
	99	102.0	102.0	101.4	101.8	102.0	101.4	101.6	101.6	100.6
	103	102.8	102.0	102.0	101.4	100.8	100.0	101.0	101.0	100.8
	104	101.8	101.6	102.0	101.2	101.2	101.2	101.4	101.4	100.6

Temperature >103 °F was considered as pyrexia

<b>Study Type</b>	Efficacy
<b>Pertaining to</b>	<i>Leptospira interrogans</i> serovar <i>grippotyphosa</i> ( <i>L. Grippotyphosa</i> )
<b>Study Purpose</b>	Demonstration of efficacy against leptospirosis caused by <i>L. Grippotyphosa</i>
<b>Product Administration</b>	One dose
<b>Study Animals</b>	15 Calves; 10 vaccinates and 5 controls. All animals were seronegative for <i>Leptospira Grippotyphosa, hardjo, pomona</i> .
<b>Challenge Description</b>	Animals were challenged 8 weeks following vaccination.
<b>Interval observed after challenge</b>	Animals were observed for 8 days post challenge. Body temperatures and blood samples were collected daily.
<b>Results</b>	<p><u>Leptospira Isolation Results in Blood:</u>  Controls: 5/5 (100%) positive  Vaccinates: 0/10 (0%) positive</p> <p><u>Temperature Results:</u>  Controls: 5/5 (100%) positive  Vaccinates: 0/10 (0%) positive</p> <p>See the following tables for individual raw data</p>
<b>USDA Approval Date</b>	12/09/1975

Blood culture for isolation of Leptospire:

Treatment Group	Animal ID	Study Day (Challenge was on Day 0)							
		1	2	3	4	5	6	7	8
CONTROLS	161	+	+	+	+	+	-	-	-
	164	+	+	+	+	-	-	-	-
	165	+	+	+	+	-	-	-	-
	241	+	+	-	-	-	-	-	-
	248	+	+	+	-	-	-	-	-
VACCINATES	130	-	-	-	-	-	-	-	-
	137	-	-	-	-	-	-	-	-
	143	-	-	-	-	-	-	-	-
	145	-	-	-	-	-	-	-	-
	155	-	-	-	-	-	-	-	-
	247	-	-	-	-	-	-	-	-
	250	-	-	-	-	-	-	-	-
	255	-	-	-	-	-	-	-	-
	260	-	-	-	-	-	-	-	-
261	-	-	-	-	-	-	-	-	

+: Leptospire detected; -: Leptospire not detected

Temperature in °F:

Treatment Group	Animal ID	Study Day (Challenge was on Day 0)								
		0	1	2	3	4	5	6	7	8
CONTROLS	161	101.6	102.4	102.2	105.4	104.8	104.4	99.4	100.6	102.8
	164	101.4	101.8	105.8	104.6	106.4	103.6	101.4	101.4	101.4
	165	102.0	102.6	102.2	104.0	104.4	104.8	101.8	102.2	102.0
	241	102.2	101.8	101.2	105.4	103.8	104.2	100.4	101.0	101.2
	248	101.6	100.4	101.8	106.0	104.4	103.6	101.0	101.2	101.6
101.4VACCINATES	130	102.0	102.0	102.0	102.4	101.6	101.4	100.2	101.4	101.8
	137	101.6	101.8	101.8	102.0	101.8	101.4	100.6	100.8	101.0
	143	102.0	101.8	101.8	101.8	102.4	101.8	100.4	99.8	101.2
	145	102.0	101.4	101.4	101.8	102.4	101.6	99.6	101.2	101.4
	155	102.2	102.0	102.0	102.4	102.2	101.2	100.0	100.4	100.8
	247	101.4	100.8	101.6	101.6	101.6	101.8	100.0	100.6	100.8
	250	101.8	102.0	102.2	101.4	101.6	101.6	101.2	101.4	101.8
	255	102.4	101.8	101.8	102.6	102.2	102.4	101.8	102.0	101.4
	260	102.0	102.6	102.8	102.4	102.0	101.6	100.0	101.2	101.2
261	102.2	100.6	101.2	101.4	101.4	101.0	100.2	100.4	100.6	

Temperature >103.5 °F was considered as pyrexia

<b>Study Type</b>	Efficacy
<b>Pertaining to</b>	<i>Leptospira borgpetersenii</i> serovar <i>hardjo</i> isolate ( <i>L. Hardjo</i> )
<b>Study Purpose</b>	Demonstration of efficacy against <i>L. hardjo</i> in calves.
<b>Product Administration</b>	Two doses administered 28 days apart subcutaneously.
<b>Study Animals</b>	Calves between 8-9 months of age, 10 controls and 11 vaccinates with two doses (28-42 days apart). All animals were seronegative for <i>Leptospira</i> serovars <i>hardjo</i> , <i>pomona</i> , <i>canicola</i> , <i>icterohaemorrhagiae</i> , and <i>grippityphosa</i> .
<b>Challenge Description</b>	Animals were challenged with <i>L. hardjo</i> 35 days after the second vaccination.
<b>Interval observed after challenge</b>	Urine cultures collected weekly following 14 days after challenge until the study finalized. Kidney tissues were examined 36 days following the challenge.
<b>Results</b>	<p>Animals were considered positive for <i>L. hardjo</i> if at least one urine sample was positive for <i>L. hardjo</i>, left kidney culture result was positive for <i>L. hardjo</i>, or a gross lesion was present on the left or right kidney.</p> <p>Urine Culture Results:  Controls: 10/10 (100%) positive  Vaccinates: 0/11 (0%) positive  PCR identity testing confirmed the presence of <i>L. hardjo</i> in all culture positive urine samples.</p> <p>Kidney Culture Results:  Controls: 10/10 (100%) positive  Vaccinates: 0/11 (0%) positive</p> <p>Kidney Gross Lesion Results:  Controls: 6/10 (60%) positive  Vaccinates: 6/11 (55%) positive</p> <p>See the following tables for the raw data.</p>
<b>USDA Approval Date</b>	05/29/2009

**Urine Culture Data**

Control ID	Day 14	Day 21	Day 28	Day 35
5892	-	+	+	+
5895	+	+	+	+
5896	-	+	+	+
5903	+	+	+	+
5910	-	+	+	+
5911	+	+	+	+
5917	+	+	+	+
5920	-	+	+	+
5927	-	+	+	+
5929	+	+	+	+
All vaccinates were negative at all sampling points.				

**Kidney Gross Lesion Data**

Control ID	Left Kidney	Right Kidney
5892	+	+
5895	+	+
5896	+	-
5903	+	+
5910	-	-
5911	-	-
5917	-	-
5920	+	+
5927	-	+
5929	-	-
Vaccinate ID	Left Kidney	Right Kidney
5884	-	+
5886	-	-
5890	-	-
5899	+	+
5905	-	-
5907	-	+
5915	-	-
5922	+	+
5925	-	-
5931	+	+
5935	+	+

<b>Study Type</b>	Efficacy
<b>Pertaining to</b>	<i>Leptospira borgpetersenii</i> serovar hardjo type hardjo bovis ( <i>Leptospira interrogans</i> serovar hardjo, <i>L. Hardjo</i> )
<b>Study Purpose</b>	Demonstration of duration of immunity against kidney infection and leptospiuria caused by <i>L. hardjo</i> in calves.
<b>Product Administration</b>	Two doses administered 4 weeks apart subcutaneously.
<b>Study Animals</b>	Cattle 7-10 months of age, 9 controls and 9 vaccinates with two doses. All animals were seronegative for <i>Leptospira</i> serovar hardjo.
<b>Challenge Description</b>	Animals were challenged with <i>L. interrogans</i> serovar hardjo bovis, strain 033, 54 weeks following first vaccination.
<b>Interval observed after challenge</b>	Urine samples were collected weekly from day of challenge for 4 weeks for culture and dark field microscopy testing. Kidneys from cattle and from hamsters inoculated with concentrated urine (5 and 10 fold) from the study animals were collected for culture.
<b>Results</b>	<p>Animals were considered positive for <i>L. hardjo</i> if at least one urine or kidney sample yielded positive per the following tests:</p> <ul style="list-style-type: none"> <li>- Urine: Culture and darkfield microscope</li> <li>- Kidney Tissue: Culture. Only one control cattle was included in culture in kidney.</li> </ul> <p><u>Urine Results:</u>  Controls: 9/9(100%) positive  Vaccinates: 0/9 (0%) positive</p> <p><u>Kidney Results:</u>  Controls: 1/1 (100%) positive  Vaccinates: 0/9 (0%) positive</p> <p>See the following tables for individual raw data.</p>
<b>USDA Approval Date</b>	05/10/2000



**Analysis of Urine for detection of Leptospires:**

Treatment Group	Animal ID	Weeks Post-Challenge							
		Dark Field Microscopy Results				Culture Results			
		2	3	4	5	2	3	4	5
CONTROLS	11	-	-	-	-	+	+	+	+
	12	-	+	+	+	+	+	+	+
	13	-	-	-	-	+	+	+	+
	14	+	+	+	+	+	+	+	+
	15	-	+	+	+	+	+	+	+
	16	-	-	-	-	+	+	+	+
	17	-	+	+	+	+	+	+	+
	18	-	+	+	+	+	-	+	+
	19	-	-	+	+	+	+	+	+
VACCINATES	1	-	-	-	-	-	-	-	-
	3	-	-	-	-	-	-	-	-
	4	-	-	-	-	-	-	-	-
	5	-	-	-	-	-	-	-	-
	6	-	-	-	-	-	-	-	-
	7	-	-	-	-	-	-	-	-
	8	-	-	-	-	-	-	-	-
	9	-	-	-	-	-	-	-	-
	10	-	-	-	-	-	-	-	-

+: Leptospires detected; -: Leptospires not detected

**Culture Results of Kidney in Cattle for detection of Leptospires**

Treatment Group	Animal ID	Kidney Section		
		1	2	3
CONTROL*	14	+	+	+
VACCINATES	1	-	-	-
	3	-	-	-
	4	-	-	-
	5	-	-	-
	6	-	-	-
	7	-	-	-
	8	-	-	-
	9	-	-	-
10	-	-	-	

\* Only one control animal was included in culture in kidney.

+: Leptospires detected; -: Leptospires not detected

**Culture Results of Kidney in Hamsters inoculated with concentrated urine for detection of Leptospire:**

Treatment Group	Cattle ID	Hamster ID	Cattle Urine Concentrated x Fold	Hamster Kidney Result
CONTROL*	14	19	10	+
VACCINATES	1	1	10	-
		2	5	-
	3	3	10	-
		4	5	-
	4	5	10	-
		6	5	-
	5	7	10	-
		8	5	-
	6	9	10	-
		10	5	-
	7	11	10	-
		12	5	-
	8	13	10	-
		14	5	-
	9	15	10	-
		16	5	-
	10	17	10	-
		18	5	-

\* Only one control cattle was included in culture in kidney in hamsters and test was conducted with urine concentrated at 10 fold only.

+: Leptopires detected; -: Leptopires not detected

<b>Study Type</b>	Efficacy
<b>Pertaining to</b>	<i>Leptospira borgpetersenii</i> serovar hardjo type hardjo bovis ( <i>Leptospira interrogans</i> serovar hardjo, <i>L. Hardjo</i> )
<b>Study Purpose</b>	Demonstration of efficacy against fetal infection
<b>Product Administration</b>	Two doses administered 4 weeks apart subcutaneously.
<b>Study Animals</b>	Heifers between 12-15 months of age, 16 vaccinates and 8 that were seronegative for <i>Leptospira</i> serovar hardjo and were bred post-vaccination.
<b>Challenge Description</b>	Animals were challenged at 4.5 to 5.5 months of gestation by vaginal and conjunctival inoculation for 3 consecutive days with <i>L. borgpetersenii</i> serovar hardjo mixed strains 203 and 197.
<b>Interval observed after challenge</b>	Urine samples were collected every 2 weeks beginning 2 weeks post challenge. Maternal kidney and placenta, and calf kidney, liver and lung tissues were collected at calving time (or abortion if happened).
<b>Results</b>	<p>Urine or tissue sample evaluated per the following tests:</p> <ul style="list-style-type: none"> <li>- Urine: Leptospiral culture and immunofluorescence</li> <li>- Tissue: Leptospiral culture, immunofluorescence, and histologic examination</li> </ul> <p><u>Urine Results from Heifers:</u>  Controls: 8/8 (100%) positive  Vaccinates: 0/16 (0%) positive</p> <p><u>Tissue Results for Maternal Kidneys:</u>  Controls: 8/8 (100% positive)  Vaccinates: 0/16 (0%) positive</p> <p><u>Tissue Results for placental and/or fetal infection (calf kidney, liver, or lung):</u>  Controls: 5/8 (62.5 %) positive  Vaccinates: 0/16 (0%) positive</p> <p>Individual raw data is not available.</p>
<b>USDA Approval Date</b>	September 12, 2002

<b>Study Type</b>	Efficacy
<b>Pertaining to</b>	<i>Leptospira borgpetersenii</i> serovar hardjo type hardjo bovis ( <i>Leptospira interrogans</i> serovar hardjo, <i>L. Hardjo</i> )
<b>Study Purpose</b>	Efficacy against renal infection and leptospiuria caused by <i>L. borgpetersenii</i> serovar hardjo bovis in calves.
<b>Product Administration</b>	Two doses administered 4 weeks apart subcutaneously.
<b>Study Animals</b>	Twenty-two (22) vaccinated and 13 control seronegative calves included in 2 trials: - Trial 1: 10 vaccinates; 6 controls - Trial 2: 12 vaccinates; 7 controls
<b>Challenge Description</b>	In Trial 1, calves were challenged 13 weeks post first vaccination, and in Trial 2, calves were challenged 6 weeks post vaccination with <i>L. interrogans</i> serovar hardjo type hardjo bovis.
<b>Interval observed after challenge</b>	In Trial 1, urine samples were collected on days 28, 34 and 41 post-challenge. Kidney were cultured. In Trial 2, urine samples were collected on days 14, 21, 28, and 35 post-challenge. Kidneys were cultured. Kidneys (4 sections) were cultured from calves with negative leptospiuria only.
<b>Results</b>	<p>Summary of results are as follows:</p> <p><u>Urine Culture Results Trial 1:</u> Controls: 4/6 (67 %) positive Vaccinates: 0/10 (0 %) positive</p> <p><u>Urine Culture Results Trial 2:</u> Controls: 7/7 (100 %) positive Vaccinates: 0/11*(0 %) positive * Only 11 vaccinates from trial 2 were tested</p> <p><u>Kidney Culture Results Trial 1*:</u> Controls: 2/2 (100 %) positive Vaccinates: 0/12 (0%) positive *kidneys were only collected from leptospiuria negative animals</p> <p><u>Kidney Culture Results Trial 2*:</u> Vaccinates: 0/12 (0%) positive *kidneys were only collected from leptospiuria negative animals</p> <p><u>Combined Urine and Kidney Culture Results for both Trial 1 and Trial 2:</u> Controls: 13/13 (100 %) positive Vaccinates: 0/22 (0 %) positive</p> <p>See the following tables for individual raw data</p>

USDA Approval Date	05/10/2000
--------------------	------------

**Results from Urine Culture for detection of Leptospires (Trial 1):**

Treatment Group	Animal ID	Study Day (Challenge was on Day 0)		
		28	34	41
CONTROLS	62	+	-	+
	64	-	-	-
	67	+	+	+
	69	+	-	+
	77	-	-	-
	78	-	-	+
VACCINATES	49	-	-	-
	50	-	-	-
	52	-	-	-
	65	-	-	-
	68	-	-	-
	71	-	-	-
	74	-	-	-
	75	-	-	-
	76	-	-	-
79	-	-	-	

+: Leptospires detected; -: Leptospires not detected

**Results from Urine Culture for detection of Leptospires (Trial 2):**

Treatment Group	Animal ID	Study Day (Challenge was on Day 0)			
		14	21	28	35
CONTROLS	1	-	+	+	+
	2	-	+	+	+
	3	-	-	+	+
	4	-	-	+	+
	5	-	+	+	+
	6	-	-	-	+
	7	-	-	-	+
VACCINATES	3	-	-	-	-
	10	-	-	-	-
	11	-	-	-	-
	2	ND	ND	ND	ND
	8	-	-	-	-
	14	-	-	-	-
	5	-	-	-	-
	12	-	-	-	-
15	-	-	-	-	

	4	-	ND	-	-
	7	-	-	-	-
	9	-	-	-	-

+: Leptospire detected; -: Leptospire not detected  
 ND: Not Done

**Results from Kidney Culture for detection of Leptospire (Trial 1):**

Treatment Group*	Animal ID	Kidney Section			
		1	2	3	4
CONTROLS	64	-	-	+	+
	77	+	+	+	+
VACCINATES	49	-	-	-	-
	50	-	-	-	-
	52	-	-	-	-
	65	-	-	-	-
	68	-	-	-	-
	71	-	-	-	-
	74	-	-	-	-
	75	-	-	-	-
	76	-	-	-	-
79	-	-	-	-	

\*: Only calves with negative leptospiuria were tested  
 +: Leptospire detected; -: Leptospire not detected

**Results from Kidney Culture for detection of Leptospire (Trial 2):**

Treatment Group	Animal ID	Kidney Section			
		1	2	3	4
VACCINATES*	3	-	-	-	-
	10	-	-	-	-
	11	-	-	-	-
	2	-	-	-	-
	8	-	-	-	-
	14	-	-	-	-
	5	-	-	-	-
	12	-	-	-	-
	15	-	-	-	-
	4	-	-	-	-
	7	-	-	-	-
	9	-	-	-	-

\*: Only calves with negative leptospiuria were tested  
 +: Leptospire detected; -: Leptospire not detected

<b>Study Type</b>	Efficacy
<b>Pertaining to</b>	<i>Leptospira borgpetersenii</i> serovar hardjo type hardjo bovis ( <i>Leptospira interrogans</i> serovar hardjo, <i>L. Hardjo</i> )
<b>Study Purpose</b>	Demonstration of efficacy against renal infection and leptospiuria caused by <i>L. hardjo</i> .
<b>Product Administration</b>	Two doses administered 4 weeks apart subcutaneously.
<b>Study Animals</b>	Heifers between 8-12 months of age, 8 controls and 8 vaccinates received two doses of vaccine. All animals were seronegative for <i>Leptospira</i> serovar hardjo.
<b>Challenge Description</b>	Animals were challenged 16 weeks following second vaccination by intraperitoneal or conjunctival inoculation for 3 consecutive days with <i>L. borgpetersenii</i> serovar hardjo strain type 203.
<b>Interval observed after challenge</b>	Urine samples collected once or twice weekly from day of challenge to necropsy day. Kidney tissues were obtained between 11 and 14 weeks after challenge.
<b>Results</b>	<p>Urine or tissue sample evaluated per the following tests:</p> <ul style="list-style-type: none"> <li>- Urine: Culture, immunofluorescence, and darkfield microscope</li> <li>- Kidney Tissue: Culture, immunofluorescence, histology and silver staining or immunochemistry</li> </ul> <p><u>Urine Results:</u>  Controls: 6/8 (75%) positive  Vaccinates: 0/8 (0%) positive</p> <p><u>Kidney Results:</u>  Controls: 8/8 (100%) positive  Vaccinates: 0/8 (0%) positive</p> <p>See the following tables for individual raw data.</p>
<b>USDA Approval Date</b>	03/29/2000

**Analysis of Urine for detection of Leptospire:**

Treatment Group	Animal ID	Study Day Post Challenge (Challenge was on Day 193)																
		2	4	6	8	10	12	14	17	21	24	28	35	42	45	49	51	56
CONTROLS	15	-	-	-	+	-	-	+	+	+	+	+	+	+	+	+	+	+
	23	-	-	-	+	-	-	-	-	+	+	+	+	+	+	+	+	+
	24	-	-	+	-	-	-	-	+	+	+	+	+	+	+	+	+	+
	28	-	-	-	+	-	-	+	+	+	+	+	+	+	+	+	+	+
	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	7	-	-	-	-	-	-	+	+	+	+	+	+	+	+	+	+	+
	16	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
	22	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
VACCINATES	11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	13	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	14	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	17	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	18	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	19	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

\*Results for urine samples are available until Day 63 post challenge and on necropsy day (see table below) only.

**Analysis of Kidney and Urine at Necropsy:**

Treatment Group	Animal ID	Detection of leptospire		Kidney Lesion Score *
		Urine	Kidney	
CONTROLS	15	+	+	1
	23	+	+	0
	24	+	+	1.5
	28	+	+	2
	2	-	+	0
	7	+	+	3.5
	16	+	+	1.5
	22	-	+	2.5
VACCINATES	11	-	-	1
	13	-	-	2
	14	-	-	2
	20	-	-	0
	12	-	-	0
	17	ND	-	0.5
	18	ND	-	2.5
	19	-	-	1

\* Lesion Score: 0= no lesions detected; 1=focal or multi focal 1- to 2-mm pale foci of lymphocytic interstitial nephritis in renal cortex; 2= multiple 2- to 5-mm foci of lymphocytic interstitial nephritis in renal cortex; 3= multiple 5- to 10-mm foci in renal cortex and medulla, with extensive lymphocytic interstitial nephritis and tubular degeneration; 4= pale foci > 10 mm foci in renal cortex and medulla, with severe lymphocytic interstitial nephritis, tubular degeneration, and fibrosis

\*\* ND: Not Done



<b>Study Type</b>	Efficacy
<b>Pertaining to</b>	<i>Leptospira borgpetersenii</i> serovar hardjo type hardjo bovis ( <i>Leptospira interrogans</i> serovar hardjo, <i>L. Hardjo</i> )
<b>Study Purpose</b>	Demonstration of efficacy against renal and reproductive tract infection and leptospiuria caused by <i>L. hardjo</i> in heifers.
<b>Product Administration</b>	Two doses administered 4 weeks apart subcutaneously.
<b>Study Animals</b>	Heifers 12 months of age, 12 controls and 12 vaccinates that received two doses of vaccine. All animals were seronegative for <i>Leptospira</i> serovar hardjo.
<b>Challenge Description</b>	Animals were challenged 19 weeks following second vaccination by conjunctival and vaginal inoculation for 3 consecutive days with <i>L. borgpetersenii</i> serovar <i>hardjo</i> strain 203 type A or 197 type B.
<b>Interval observed after challenge</b>	Urine samples were collected weekly from two weeks post-challenge to necropsy day. Tissues (kidney, uterus, oviduct) were obtained at necropsy between 10 and 12 weeks after challenge.
<b>Results</b>	<p>Urine or tissue sample evaluated per the following tests:</p> <ul style="list-style-type: none"> <li>- Urine: Culture, immunofluorescence, PCR, and darkfield microscopy</li> <li>- Tissue: Culture, immunofluorescence, histopathology and immunochemistry</li> </ul> <p><b>Summary of results</b></p> <p><u>Urine Results</u>  Controls: 12/12 (100%) positive  Vaccinates: 0/11* (0%) positive</p> <p><u>Kidney Results (leptospire and/or lesion score <math>\geq 1</math>) :</u>  Controls: 12/12 (100%) positive  Vaccinates: 4/11* (36%) positive</p> <p><u>Reproductive Tract Results:</u>  Controls: 10/12 (83%) positive  Vaccinates: 0/11* (0%) positive</p> <p>* One heifer from vaccinated group died of unrelated causes (bloat) before the end of study.</p> <p>See the following tables for individual raw data</p>
<b>USDA Approval Date</b>	03/29/2000

**Analysis of Urine for detection of Leptospires:**

Treatment Group	Animal ID	Study Day (Challenge was on Day 0)								
		0	14	21	28	35	42	49	56	63 <sup>‡</sup>
CONTROLS	123	-	-	+	+	+	+	+	+	+
	124	-	-	+	+	+	+	+	+	+
	131	-	+	+	+	+	+	+	+	+
	132	-	+	+	+	+	+	+	+	+
	138	-	-	+	+	+	+	+	+	+
	143	-	+	+	+	+	+	+	+	+
	144	-	-	+	+	+	+	+	+	+
	146	-	-	+	+	+	+	+	+	+
	150	-	+	+	+	+	+	+	+	+
	128*	-	+	+	+	+	+	+	+	+
	135*	-	-	+	+	+	+	+	+	+
148*	-	-	-	-	+	+	+	+	+	
VACCINATES	125	-	-	-	-	-	-	-	-	-
	127	-	-	-	-	-	-	-	-	ND**
	130	-	-	-	-	-	-	-	-	-
	133	-	-	-	-	-	-	-	-	-
	136	-	-	-	-	-	-	-	-	-
	139	-	-	-	-	-	-	-	-	-
	142	-	-	-	-	-	-	-	-	-
	145	-	-	-	-	-	-	-	-	-
	149	-	-	-	-	-	-	-	-	-
	129*	-	-	-	-	-	-	-	-	-
	137*	-	-	-	-	-	-	-	-	-
140*	-	-	-	-	-	-	-	-	-	

+: Leptospires detected; -: Leptospires not detected

\*: Heifers with \* were challenged with *L. borgpetersenii* serovar *hardjo* strain type A 203. The other animals were challenged with *L. borgpetersenii* serovar *hardjo* strain type B 197.

‡: Results for urine samples are available until Day 63 post challenge and on necropsy day (see table below) only.

\*\* Heifer 127 died of unrelated causes (bloat) before the end of study.

ND: Not Done

**Analysis of Kidney, Urine, and Reproductive Tract at Necropsy:**

Treatment Group	Animal ID	Detection of leptospires				Kidney Lesion Score <sup>€</sup>
		Urine	Kidney	Uterus	Oviduct	
CONTROLS	123	+	+	+	+	0
	124	+	+	-	+	3
	131	+	+	-	+	0
	132	+	+	+	-	0
	138	+	+	-	+	1
	143	+	+	+	+	0
	144	-	+	-	-	0
	146	+	+	+	+	2
	150	+	+	+	-	0
	128*	+	+	-	+	ND
	135*	+	+	-	-	0

	148*	+	+	+	+	3
<b>VACCINATES</b>	125	-	-	-	-	0
	127**	ND	ND	ND	ND	ND
	130	-	-	-	-	0
	133	-	-	-	-	0
	136	-	-	-	-	0
	139	ND	-	-	-	1
	142	-	-	-	-	0
	145	-	-	-	-	0
	149	-	-	-	-	1
	129*	-	-	-	-	0
	137*	-	-	-	-	0
	140*	-	-	-	-	3

+: Leptospire detected; -: Leptospire not detected

\* Heifers with \* were challenged with *L. borgpetersenii* serovar *hardjo* strain type A 203. The other animals were challenged with *L. borgpetersenii* serovar *hardjo* strain type B 197.

\*\* Heifer 127 died of unrelated causes (bloat) before the end of study.

€ Lesion Score: 0= no lesions detected; 1=focal or multi focal 1- to 2-mm pale foci of lymphocytic interstitial nephritis in renal cortex; 2=multiple 2- to 5-mm foci of lymphocytic interstitial nephritis in renal cortex; 3=multiple 5- to 10-mm foci in renal cortex and medulla, with extensive lymphocytic interstitial nephritis and tubular degeneration; 4=pale foci > 10 mm foci in renal cortex and medulla, with severe lymphocytic interstitial nephritis, tubular degeneration, and fibrosis

ND: Not Done

**Summary Table for Kidney, Urine, and Reproductive Tract (Consolidation results from urine samples and samples from necropsy day):**

Treatment Group	Animal ID	Detection of leptospire		
		Urine	Kidney	Reproductive Tract
<b>CONTROLS</b>	123	+	+	+
	124	+	+	+
	131	+	+	+
	132	+	+	+
	138	+	+	+
	143	+	+	+
	144	+	+	-
	146	+	+	+
	150	+	+	+
	128*	+	+	+
	135*	+	+	-
	148*	+	+	+
<b>VACCINATES</b>	125	-	-	-
	127**	ND	ND	ND
	130	-	-	-
	133	-	-	-
	136	-	-	-
	139	ND	-	-
	142	-	-	-
	145	-	-	-
	149	-	-	-
	129*	-	-	-

	137*	-	-	-
	140*	-	-	-

\* Reproductive tract includes oviduct and uterus.

\*\* Heifer 127 died of unrelated causes (bloat) before the end of study.

<b>Study Type</b>	Efficacy
<b>Pertaining to</b>	<i>Leptospira interrogans</i> serovar icterohaemorrhagiae ( <i>L. icterohaemorrhagiae</i> )
<b>Study Purpose</b>	Demonstration of efficacy against leptospirosis caused by <i>L. icterohaemorrhagiae</i>
<b>Product Administration</b>	One dose administered intramuscularly
<b>Study Animals</b>	15 Calves approximately 6 months of age; 10 vaccinates and 5 controls. All animals were seronegative for <i>Leptospira canicola</i> , <i>icterohaemorrhagiae</i> , <i>hardjo</i> , <i>grippotyphosa</i> , <i>pomona</i> .
<b>Challenge Description</b>	Animals were challenged 7 weeks following vaccination.
<b>Interval observed after challenge</b>	Animals were observed for 8 days post challenge. Body temperatures and blood samples were collected daily.
<b>Results</b>	<p><u>Leptospira Isolation Results in Blood:</u>  Controls: 4/5 (80 %) positive  Vaccinates: 0/10 (0 %) positive</p> <p><u>Temperature Results:</u>  Controls: 5/5 (100 %) positive  Vaccinates: 0/10 (0 %) positive</p> <p>See the following tables for individual raw data</p>
<b>USDA Approval Date</b>	09/13/1977

Blood culture for isolation of Leptospire:

Treatment Group	Animal ID	Study Day (Challenge was on Day 0)							
		1	2	3	4	5	6	7	8
CONTROLS	66	+	+	-	-	-	-	-	-
	71	+	+	-	-	-	-	-	-
	79	+	+	+	-	-	-	-	-
	113	+	+	-	-	-	-	-	-
	120	-	-	-	-	-	-	-	-
VACCINATES	58	-	-	-	-	-	-	-	-
	69	-	-	-	-	-	-	-	-
	80	-	-	-	-	-	-	-	-
	102	-	-	-	-	-	-	-	-
	107	-	-	-	-	-	-	-	-
	114	-	-	-	-	-	-	-	-
	121	-	-	-	-	-	-	-	-
	122	-	-	-	-	-	-	-	-
	124	-	-	-	-	-	-	-	-
128	-	-	-	-	-	-	-	-	

+: Leptospire detected; -: Leptospire not detected

Temperature in °F:

Treatment Group	Animal ID	Study Day (Challenge was on Day 0)								
		0	1	2	3	4	5	6	7	8
CONTROLS	66	101.0	103.6	104.8	101.0	100.8	101.2	100.0	100.4	101.0
	71	101.0	104.0	102.0	102.2	101.8	101.4	100.4	102.0	101.4
	79	101.6	103.0	104.8	103.0	102.4	102.0	102.0	101.8	102.4
	113	101.4	104.4	104.2	102.8	100.8	100.2	101.0	101.2	101.4
	120	100.0	105.4	103.0	102.6	102.0	101.2	100.6	101.0	100.8
VACCINATES	58	99.8	101.6	101.4	101.4	101.8	101.6	101.0	101.2	102.4
	69	101.0	100.2	102.4	102.4	102.0	101.2	101.2	101.2	101.6
	80	101.4	101.8	101.4	101.0	102.0	101.6	100.6	101.0	101.6
	102	101.2	101.6	101.4	102.0	102.0	100.6	101.4	101.0	102.0
	107	101.2	102.0	101.8	99.8	101.8	101.0	100.8	101.6	101.4
	114	101.0	101.8	101.6	101.6	101.6	102.0	101.0	101.4	101.4
	121	101.4	101.8	102.0	101.8	101.8	101.4	102.0	101.2	102.2
	122	101.2	100.4	101.8	102.0	101.6	101.6	101.8	101.8	101.4
	124	101.4	101.4	101.4	101.0	101.6	100.8	101.0	101.2	101.8
128	101.2	101.4	101.2	101.4	102.4	101.4	100.8	102.2	101.2	

Temperature >103 °F was considered as pyrexia

<b>Study Type</b>	Efficacy
<b>Pertaining to</b>	<i>Leptospira interrogans</i> serovar <i>pomona</i> ( <i>L. pomona</i> )
<b>Study Purpose</b>	Demonstration of efficacy against leptospirosis caused by <i>L. Pomona</i>
<b>Product Administration</b>	One dose
<b>Study Animals</b>	15 Calves; 10 vaccinates and 5 controls. All animals were seronegative for <i>Leptospira grippotyphosa</i> , <i>hardjo</i> , <i>pomona</i> .
<b>Challenge Description</b>	Animals were challenged 5 weeks following vaccination.
<b>Interval observed after challenge</b>	Animals were observed for 8 days post challenge. Body temperatures and blood samples were collected daily.
<b>Results</b>	<p><u>Leptospira Isolation Results in Blood:</u>  Controls: 5/5 (100%) positive  Vaccinates: 0/10 (0%) positive</p> <p><u>Temperature Results:</u>  Controls: 5/5 (100%) positive  Vaccinates: 0/10 (0%) positive</p> <p>See the following tables for individual raw data</p>
<b>USDA Approval Date</b>	12/09/1975

Blood culture for isolation of Leptospire:

Treatment Group	Animal ID	Study Day (Challenge was on Day 0)							
		1	2	3	4	5	6	7	8
CONTROLS	159	+	+	+	+	-	-	-	-
	163	+	+	+	-	-	-	-	-
	244	+	+	+	-	-	-	-	-
	252	+	+	+	-	-	-	-	-
	265	+	+	+	-	-	-	-	-
VACCINATES	134	-	-	-	-	-	-	-	-
	135	-	-	-	-	-	-	-	-
	142	-	-	-	-	-	-	-	-
	149	-	-	-	-	-	-	-	-
	151	-	-	-	-	-	-	-	-
	242	-	-	-	-	-	-	-	-
	245	-	-	-	-	-	-	-	-
	246	-	-	-	-	-	-	-	-
	257	-	-	-	-	-	-	-	-
	262	-	-	-	-	-	-	-	-

+: Leptospire detected; -: Leptospire not detected

Temperature in °F:

Treatment Group	Animal ID	Study Day (Challenge was on Day 0)								
		0	1	2	3	4	5	6	7	8
CONTROLS	159	102.6	102.2	104.6	105.8	106.2	103.4	100.8	102.0	102.8
	163	102.6	102.2	105.6	106.0	106.6	103.2	101.0	103.0	102.6
	244	101.6	102.2	103.2	104.6	103.8	102.4	101.8	101.8	102.4
	252	102.6	102.4	103.0	107.4	104.6	103.0	102.2	103.0	103.0
	265	101.8	102.8	103.6	106.4	105.6	103.0	102.0	103.8	102.0
101.4VACCINATES	134	102.2	101.4	101.6	101.6	102.0	102.2	101.4	102.0	103.0
	135	102.6	102.6	102.6	102.4	103.2	102.8	102.0	102.8	102.4
	142	102.6	102.6	101.6	102.0	102.0	102.8	99.8	102.2	102.6
	149	102.4	102.0	102.6	102.0	101.6	102.0	101.6	102.0	102.4
	151	101.6	101.4	102.0	101.4	101.4	101.6	101.4	102.2	101.8
	242	101.6	101.2	101.6	102.0	101.6	102.0	100.8	101.4	101.0
	245	102.8	102.6	102.4	102.0	101.8	102.6	101.0	102.6	102.8
	246	102.4	101.6	102.0	102.0	102.2	102.6	101.0	102.0	102.6
	257	102.2	101.6	101.0	101.6	102.0	101.6	101.2	101.6	101.0
	262	102.6	102.0	101.0	102.0	101.6	101.8	101.0	102.6	101.4

Temperature >103.5 °F was considered as pyrexia



<b>Study Type</b>	Safety																																																												
<b>Pertaining to</b>	ALL																																																												
<b>Study Purpose</b>	To demonstrate safety under field conditions																																																												
<b>Product Administration</b>	2 doses administered either intramuscularly (IM) or subcutaneously (SQ) 28 days apart.																																																												
<b>Study Animals</b>	The study was conducted at 3 locations with 300 head of cattle, including pregnant cows, that ranged in age from less than 4 weeks to 14 years. The animals were allotted to non-vaccinated control (100), SQ vaccination (100), and IM vaccination (100) treatment groups.																																																												
<b>Challenge Description</b>	Not applicable																																																												
<b>Interval observed after challenge</b>	Animals were observed for 1 hour after each injection, weekly for injection site reactions, and daily for 59 days after the first injection.																																																												
<b>Results</b>	<p><b>Adverse Events (AEs) were recorded</b></p> <table border="1"> <thead> <tr> <th colspan="2">Number of animals</th> <th rowspan="2">Animal with no AE (%)</th> <th rowspan="2">Animals with AE (%)</th> </tr> </thead> <tbody> <tr> <td><b>Enrolled</b></td> <td>300</td> <td></td> <td></td> </tr> <tr> <td><b>Completed the study</b></td> <td>298</td> <td>293 (98.3)</td> <td>5 (1.7)</td> </tr> <tr> <td><b>Did not Complete the study</b></td> <td>2</td> <td>1 †</td> <td>1</td> </tr> <tr> <td><b>Total</b></td> <td>300</td> <td>294 (98.0)</td> <td>6 (2.0)</td> </tr> </tbody> </table> <p>†Removed due to aggressive behavior.</p> <table border="1"> <thead> <tr> <th rowspan="3">Abnormal Health Events (VeDDRA Code)</th> <th colspan="6">Number of Adverse Event Observations</th> </tr> <tr> <th colspan="2">Pregnant</th> <th colspan="2">Minimum Age calves (≤ 4 weeks)</th> <th colspan="2">Older Calves (≥2 months)</th> </tr> <tr> <th>Control</th> <th>Vaccinate</th> <th>Control</th> <th>Vaccinate</th> <th>Control</th> <th>Vaccinate</th> </tr> </thead> <tbody> <tr> <td>Death</td> <td>0/50</td> <td>0/100</td> <td>0/20</td> <td>1<sup>^</sup>/40</td> <td>0/30</td> <td>0/60</td> </tr> <tr> <td>Depression</td> <td>0/50</td> <td>0/100</td> <td>0/20</td> <td>0/40</td> <td>1<sup>#</sup>/30</td> <td>0/60</td> </tr> <tr> <td>Laceration</td> <td>0/50</td> <td>1/100</td> <td>0/20</td> <td>0/40</td> <td>0/30</td> <td>0/60</td> </tr> </tbody> </table> <p><sup>^</sup>Calf died on Day 8 due to diarrhea.  <sup>#</sup> Calf slightly depressed on final observation (Day 59).  None of these Adverse Events were considered by the study Investigator to be related to vaccination.</p> <p><b>Injection Site Reactions</b>  No animals on this study had visually observable injection site reactions following SQ or IM vaccination.</p>	Number of animals		Animal with no AE (%)	Animals with AE (%)	<b>Enrolled</b>	300			<b>Completed the study</b>	298	293 (98.3)	5 (1.7)	<b>Did not Complete the study</b>	2	1 †	1	<b>Total</b>	300	294 (98.0)	6 (2.0)	Abnormal Health Events (VeDDRA Code)	Number of Adverse Event Observations						Pregnant		Minimum Age calves (≤ 4 weeks)		Older Calves (≥2 months)		Control	Vaccinate	Control	Vaccinate	Control	Vaccinate	Death	0/50	0/100	0/20	1 <sup>^</sup> /40	0/30	0/60	Depression	0/50	0/100	0/20	0/40	1 <sup>#</sup> /30	0/60	Laceration	0/50	1/100	0/20	0/40	0/30	0/60
Number of animals		Animal with no AE (%)	Animals with AE (%)																																																										
<b>Enrolled</b>	300																																																												
<b>Completed the study</b>	298	293 (98.3)	5 (1.7)																																																										
<b>Did not Complete the study</b>	2	1 †	1																																																										
<b>Total</b>	300	294 (98.0)	6 (2.0)																																																										
Abnormal Health Events (VeDDRA Code)	Number of Adverse Event Observations																																																												
	Pregnant		Minimum Age calves (≤ 4 weeks)		Older Calves (≥2 months)																																																								
	Control	Vaccinate	Control	Vaccinate	Control	Vaccinate																																																							
Death	0/50	0/100	0/20	1 <sup>^</sup> /40	0/30	0/60																																																							
Depression	0/50	0/100	0/20	0/40	1 <sup>#</sup> /30	0/60																																																							
Laceration	0/50	1/100	0/20	0/40	0/30	0/60																																																							

	<p><b>Pregnant cows</b> 150 cows were confirmed to be pregnant on the day of the first vaccination of which 138 were in the second semester and 12 were in the third trimester.</p> <table border="1" data-bbox="587 479 959 831"> <tr> <td data-bbox="587 479 730 517"></td> <td colspan="2" data-bbox="730 479 959 517"></td> </tr> <tr> <td data-bbox="587 517 730 689"><b>Abnormal Health Events (VeDDRA Code)</b></td> <td colspan="2" data-bbox="730 517 959 689" style="text-align: center;"><b>Pregnant</b></td> </tr> <tr> <td data-bbox="587 689 730 728"></td> <td data-bbox="730 689 826 728">Control</td> <td data-bbox="826 689 959 728">Vaccinate</td> </tr> <tr> <td data-bbox="587 728 730 766">Abortion</td> <td data-bbox="730 728 826 766">0/50</td> <td data-bbox="826 728 959 766">2*/100</td> </tr> <tr> <td data-bbox="587 766 730 804">Stillbirth</td> <td data-bbox="730 766 826 804">1**/50</td> <td data-bbox="826 766 959 804">0/100</td> </tr> <tr> <td data-bbox="587 804 730 831">Metritis</td> <td data-bbox="730 804 826 831">1**/50</td> <td data-bbox="826 804 959 831">0/100</td> </tr> </table> <p>*Cows aborted before conclusion of the study. Fetuses were not recovered. **Same cow observed to have premature delivery with stillborn calf on Day 45; cause of stillborn calf undetermined. Cow diagnosed with metritis in Day 59.</p>				<b>Abnormal Health Events (VeDDRA Code)</b>	<b>Pregnant</b>			Control	Vaccinate	Abortion	0/50	2*/100	Stillbirth	1**/50	0/100	Metritis	1**/50	0/100
<b>Abnormal Health Events (VeDDRA Code)</b>	<b>Pregnant</b>																		
	Control	Vaccinate																	
Abortion	0/50	2*/100																	
Stillbirth	1**/50	0/100																	
Metritis	1**/50	0/100																	
<b>USDA Approval Date</b>	05/14/2008																		

<b>Study Type</b>	Safety																																						
<b>Pertaining to</b>	ALL																																						
<b>Study Purpose</b>	To demonstrate safety under field conditions																																						
<b>Product Administration</b>	IBR-BVD-PI3-BRSV-VL5 or IBR-BVD-PI3-BRSV-L5 was administered either intramuscularly (IM) or subcutaneously (SQ), followed by a second vaccination 28 days later with BRSV-VL5 or BRSV-L5, respectively																																						
<b>Study Animals</b>	The study was conducted at 3 locations with 990 head of cattle (661 vaccinates and 329 controls). The animals were allotted to non-vaccinated control (329), subcutaneous (SQ) vaccination with IBR-BVD-PI3-BRSV-VL5 (210), SQ vaccination with IBR-BVD-PI3-BRSV-L5 (120), intramuscular (IM) vaccination with IBR-BVD-PI3-BRSV-VL5 (211) and IM vaccination with IBR-BVD-PI3-BRSV-L5 (120) treatment groups.																																						
<b>Challenge Description</b>	Not applicable																																						
<b>Interval observed after challenge</b>	Animals were observed for 1 to 3 hours after each vaccination, then once weekly for injection site reactions until day 49 after first injection or until resolution. Animals were also observed daily for general health observations for 49 days after the first injection.																																						
<b>Results</b>	<table border="1"> <thead> <tr> <th><b>Cattle Enrolled by Age</b></th> <th><b>Vaccinate</b></th> <th><b>Control</b></th> </tr> </thead> <tbody> <tr> <td>17-43 days</td> <td>198</td> <td>101</td> </tr> <tr> <td>10-11 months</td> <td>40</td> <td>20</td> </tr> <tr> <td>13 months</td> <td>60</td> <td>30</td> </tr> <tr> <td>Pregnant 14-27 months</td> <td>200</td> <td>98</td> </tr> <tr> <td>Pregnant 1-6 years</td> <td>163</td> <td>80</td> </tr> </tbody> </table> <p><b>Adverse Events (AEs)</b></p> <table border="1"> <thead> <tr> <th colspan="2"><b>Number of animals</b></th> <th rowspan="2"><b>Animal with no AE (%)</b></th> <th rowspan="2"><b>Animals with AE (%)</b></th> </tr> <tr> <th><b>Enrolled</b></th> <th></th> </tr> </thead> <tbody> <tr> <td></td> <td>990</td> <td></td> <td></td> </tr> <tr> <td><b>Completed the study</b></td> <td>989</td> <td>959 (96.9)</td> <td>30 (3.0)</td> </tr> <tr> <td><b>Did not Complete the study</b></td> <td>1*</td> <td>1</td> <td>0</td> </tr> </tbody> </table> <p>* Died from punctured abomasum before second vaccination.</p>			<b>Cattle Enrolled by Age</b>	<b>Vaccinate</b>	<b>Control</b>	17-43 days	198	101	10-11 months	40	20	13 months	60	30	Pregnant 14-27 months	200	98	Pregnant 1-6 years	163	80	<b>Number of animals</b>		<b>Animal with no AE (%)</b>	<b>Animals with AE (%)</b>	<b>Enrolled</b>			990			<b>Completed the study</b>	989	959 (96.9)	30 (3.0)	<b>Did not Complete the study</b>	1*	1	0
<b>Cattle Enrolled by Age</b>	<b>Vaccinate</b>	<b>Control</b>																																					
17-43 days	198	101																																					
10-11 months	40	20																																					
13 months	60	30																																					
Pregnant 14-27 months	200	98																																					
Pregnant 1-6 years	163	80																																					
<b>Number of animals</b>		<b>Animal with no AE (%)</b>	<b>Animals with AE (%)</b>																																				
<b>Enrolled</b>																																							
	990																																						
<b>Completed the study</b>	989	959 (96.9)	30 (3.0)																																				
<b>Did not Complete the study</b>	1*	1	0																																				

**Frequency of Adverse Event observations per category of calves:**

Observations	Minimum age calves (17 to 43 days of age) Number of animals				
	Controls	Vaccinates			
		SQ (1)	IM (1)	SQ (2)	IM (2)
Bloat	1	0	0	0	1
Ear drop	0	0	0	1	1
Depression	1	0	0	0	0
Diarrhea	1	0	0	0	0
Death*	0	0	0	0	1
Depression with ear drop	0	0	0	1	1
Lameness	2	0	0	0	0
Enterotoxemia	1	0	0	0	0
Draining ear	1	0	0	0	0

\* Animal died from complications from bloat.

(1) Vaccination with IBR-BVD-PI3-BRSV-L5 and BRSV-L5

(2) Vaccination with IBR-BVD-PI3-BRSV-VL5 and BRSV-VL5

These Adverse Events were considered by the Regional Investigator not to be related to the use of the vaccine.

Observations	Older calves (10-13 months of age) Number of animals				
	Controls	Vaccinates			
		SQ (1)	IM (1)	SQ (2)	IM (2)
Foot Rot	1	1	1	0	0

(1) Vaccination with IBR-BVD-PI3-BRSV-L5 and BRSV-L5

(2) Vaccination with IBR-BVD-PI3-BRSV-VL5 and BRSV-VL5

These Adverse Events were considered by the Regional Investigator not to be related to the use of the vaccine.

**Frequency of Adverse Event observations per category of pregnant heifers and cows:**

Cattle were confirmed pregnant on day of first vaccination.

Cattle Enrolled by Trimeser	Vaccinate	Control
1	108	53
2	155	77
3	100	48

Observations	Pregnant cattle Number of animals				
	Controls	Vaccinates			
		SQ (1)	IM (1)	SQ (2)	IM (2)
Abortion	4*	2**	1	0	0
Metritis	0	1**	0	0	0

\*Cause of abortions was undetermined.

\*\* One animal was observed with abortion and metritis; cause undetermined.

(1) Vaccination with IBR-BVD-PI3-BRSV-L5 and BRSV-L5

(2) Vaccination with IBR-BVD-PI3-BRSV-VL5 and BRSV-VL5

Observations	Pregnant cattle Number of animals				
	Controls	Vaccinates			
		SQ (1)	IM (1)	SQ (2)	IM (2)
Foot rot	2	1	0	0	0
Keratitis	1	0	0	1	0
Cracked hoof	1	0	0	0	0
Lameness/edema	0	0	0	0	1

(1) Vaccination with IBR-BVD-PI3-BRSV-L5 and BRSV-L5

(2) Vaccination with IBR-BVD-PI3-BRSV-VL5 and BRSV-VL5

These Adverse Events were considered by the Regional Investigator not to be related to the use of the vaccine.

### Injection Site Reactions per category of age:

Pregnant Cattle														
Controls*		SQ (1)			IM (1)			SQ (2)			IM (2)			
1st Injection														
0.5-2 cm	2-5 cm	0.5-2 cm	2-5 cm	>5 cm	0.5-2 cm	2-5 cm	>5 cm	0.5-2 cm	2-5 cm	>5 cm	0.5-2 cm	2-5 cm	>5 cm	
1	1	10	1	0	1	0	0	0	0	0	3**	0	0	
2nd injection														
2	0	0	0	0	0	0	0	2	0	0	4	2	0	

Minimum Age Calves														
Controls*		SQ (1)			IM (1)			SQ (2)			IM (2)			
1st Injection														
0.5-2 cm	2-5 cm	0.5-2 cm	2-5 cm	>5 cm	0.5-2 cm	2-5 cm	>5 cm	0.5-2 cm	2-5 cm	>5 cm	0.5-2 cm	2-5 cm	>5 cm	
0	0	n/a	n/a	n/a	n/a	n/a	n/a	0	0	0	0	0	0	
2nd injection														
3	0	n/a	n/a	n/a	n/a	n/a	n/a	15	2	0	5	0	0	

<b>Older Calves</b>													
Controls*		SQ (1)			IM (1)			SQ (2)			IM (2)		
<b>1st Injection</b>													
0.5-2 cm	2-5 cm	0.5-2 cm	2- 5 cm	>5 cm	0.5-2 cm	2-5 cm	>5 cm	0.5- 2 cm	2- 5 cm	>5 cm	0.5- 2 cm	2- 5 cm	>5 cm
1	0	2**	0	4**	5**	5**	0	0	0	0	0	0	0
<b>2nd injection</b>													
0	0	0	0	0	0	0	0	0	0	0	0	0	0
<p>* Controls did not have Injection Site Reactions greater than 2-5 cm</p> <p>** In the case where an individual animal had an injection site reaction present on multiple weekly observations, only the largest reaction score is represented in the Table.</p> <p>n/a: Minimum age calves were vaccinated only with IBR-BVD-PI3-BRSV-VL5 and BRSV-VL5</p> <p>(1): Vaccination with IBR-BVD-PI3-BRSV-L5 and BRSV-L5</p> <p>(2): Vaccination with IBR-BVD-PI3-BRSV-VL5 and BRSV-VL5</p> <p>The Injection Sites Reactions resolved without incident within 30 days following each vaccination with the exception of one pregnant cow, vaccinated IM with IBR-BVD-PI3-BRSV-VL5 and BRSV-VL5, which was completely resolved on day 58.</p>													
<b>USDA Approval Date</b>		05/14/2008											

<b>Study Type</b>	Safety																																												
<b>Pertaining to</b>	ALL																																												
<b>Study Purpose</b>	To demonstrate safety under field conditions.																																												
<b>Product Administration</b>	Two doses administered either subcutaneously (SQ) or intramuscularly (IM) 28 days apart. Second dose of vaccine consisted of Bacterin product only																																												
<b>Study Animals</b>	307 beef calves, approximately 7 weeks (104 calves) or 9 months of age (203 calves), at each of 3 sites: Control (103 calves), SC administration of product (102 calves) and IM administration of product (102 calves) treatment groups.																																												
<b>Challenge Description</b>	Not Applicable																																												
<b>Interval observed after challenge</b>	Calves were observed daily for 48 days.																																												
<b>Results</b>	<table border="1"> <thead> <tr> <th colspan="2"><b>Animals Total</b></th> <th><b>Animals with no Adverse Event Observations (%)</b></th> <th><b>Animals with Adverse Event Observations (%)</b></th> </tr> </thead> <tbody> <tr> <td><b>Completed the study</b></td> <td>306</td> <td>301 (98.4)</td> <td>5 (1.6)</td> </tr> <tr> <td><b>Did not Complete the study</b></td> <td>1</td> <td>0</td> <td>1</td> </tr> <tr> <td><b>Total</b></td> <td>307</td> <td>301 (98.0)</td> <td>6 (2)</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th rowspan="2"><b>Abnormal Health Events (VeDDRA Code)</b></th> <th colspan="2"><b>Number of Adverse Event Observations</b></th> </tr> <tr> <th>Controls</th> <th>Vaccinates</th> </tr> </thead> <tbody> <tr> <td>Abnormal Breathing</td> <td>0</td> <td>1</td> </tr> <tr> <td>Lameness</td> <td>0</td> <td>2*</td> </tr> <tr> <td>Depression</td> <td>1**</td> <td>0</td> </tr> <tr> <td>Dyspnea</td> <td>1**</td> <td>0</td> </tr> <tr> <td>Death</td> <td>1**</td> <td>0</td> </tr> <tr> <td>Anorexia</td> <td>0</td> <td>2</td> </tr> <tr> <td>Cough</td> <td>0</td> <td>1</td> </tr> </tbody> </table> <p>*: Same calf observed on 2 different days. This calf had a lame right hind (physical injury). After appearing to resolve, the lameness was observed again and did not resolve by the end of the study.</p> <p>**Same calf observed on 3 different days (diagnosed post necropsy with fibronectrotizing bronchopneumonia).</p>			<b>Animals Total</b>		<b>Animals with no Adverse Event Observations (%)</b>	<b>Animals with Adverse Event Observations (%)</b>	<b>Completed the study</b>	306	301 (98.4)	5 (1.6)	<b>Did not Complete the study</b>	1	0	1	<b>Total</b>	307	301 (98.0)	6 (2)	<b>Abnormal Health Events (VeDDRA Code)</b>	<b>Number of Adverse Event Observations</b>		Controls	Vaccinates	Abnormal Breathing	0	1	Lameness	0	2*	Depression	1**	0	Dyspnea	1**	0	Death	1**	0	Anorexia	0	2	Cough	0	1
<b>Animals Total</b>		<b>Animals with no Adverse Event Observations (%)</b>	<b>Animals with Adverse Event Observations (%)</b>																																										
<b>Completed the study</b>	306	301 (98.4)	5 (1.6)																																										
<b>Did not Complete the study</b>	1	0	1																																										
<b>Total</b>	307	301 (98.0)	6 (2)																																										
<b>Abnormal Health Events (VeDDRA Code)</b>	<b>Number of Adverse Event Observations</b>																																												
	Controls	Vaccinates																																											
Abnormal Breathing	0	1																																											
Lameness	0	2*																																											
Depression	1**	0																																											
Dyspnea	1**	0																																											
Death	1**	0																																											
Anorexia	0	2																																											
Cough	0	1																																											

<b>Adverse Event Observations</b>	<b>Number of Animals (%)</b>			
	Controls		Vaccinates	
<b>Normal</b>	102		199	
<b>Abnormal</b>	1 (0.97)		5 (2.45)	

None of the Adverse Events were considered by the study Investigator to be related to vaccination.

<b>Treatment Group</b>	<b>Total Number of Animals</b>	<b>Number of Animals with Injection Site Reactions (%)</b>			
		<b>7-week-old calves</b>	<b>9-month-old calves</b>	<b>Injection Site Reaction in cm</b>	
				<b>&lt; 1.5</b>	<b>1.5 to 5</b>
<b>Controls</b>	103	0	0	0	0
<b>SQ</b>	102	7 (6.93)	1 (0.99)	7	1
<b>IM</b>	102	1 (0.98)	0 (0)	1	0

All injection site reactions were resolved by day 48.

<b>USDA Approval Date</b>	06/17/2009
---------------------------	------------